Biomed Industries will present results from its Phase 2 clinical trial of NA-931, an oral quadruple-receptor agonist for the treatment of obesity, at the European Association for the Study of Diabetes (EASD) meeting in Vienna, Austria, September 15–19, according to the company.
NA-931, also branded Bioglutide™, targets four metabolic hormone receptors—IGF-1, GLP-1, GIP and glucagon—in oral capsule form, offering a potential alternative to injectable therapies. The Phase 2 study was randomized, double-blind, placebo-controlled and parallel-arm, enrolling adults with obesity (BMI ≥ 30 kg/m²) or overweight individuals (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity.
The company says the trial confirmed robust efficacy and a favourable safety profile, with weight-loss results comparable to leading approved and late-stage injectable treatments, and significantly fewer, milder side-effects. Dr. Tran will also present findings on the relationship between obesity and Alzheimer’s disease, examining NA-831 and NA-931 as part of that research.
According to the company, more than 650 million people worldwide are affected by obesity, and by 2035 more than half the global population may be overweight or obese. NA-931 could address this growing need with a safe, effective, and accessible oral therapy.
